Introduction
Iron deficiency (ID) and ID-associated anemia are the most common nutritional deficiencies in pregnant women. The incidence of anemia during pregnancy is highest in Asia, according to statistics from the World Health Organization (1) . Using the diagnostic criteria of serum ferritin (SF) <20 μg/L and normal hemoglobin, the prevalence of ID in pregnant women has been reported as 42.6% overall and 38.8% during the second trimester (2, 3) . Using total body iron <0 mg/kg as the diagnostic criterion, the incidence of ID during the second trimester in the United States was 14.3±2.1% from 1999 to 2006 (4) . ID during pregnancy significantly increases the risk of hypertension, premature delivery, fetal growth restriction, low birth weight babies, and fetal death.
Triiodothyronine (T3) and thyroxine (T4) are associated with the development of the fetal nervous system. Hypothyroidism is a relatively common disorder during pregnancy. In their cohort study, Shan et al. reported a 5.96% incidence of subclinical hypothyroidism and a 2.29% rate of overt hypothyroidism in Chinese women at 20 weeks gestation (5) . Thyroid dysfunction in pregnant women is associated with hypertension during pregnancy, gestational diabetes mellitus, spontaneous abortion, fetal dysplasia, and neuropsychological deficiency in children (6) (7) (8) . When iodine intake is adequate, the most common cause of hypothyroidism is autoimmune thyroid disease (Hashimoto's thyroiditis) (9) . Thyroid autoantibodies are present in 2 to 17% of pregnant women.The prevalence of antibodies varies with ethnicity(10)The main adverse obstetric outcomes associated with autoimmune thyroid disease are an increased likelihood of infertility and recurrent abortion, premature delivery, low birth weight infants, and postpartum thyroiditis (11) .
In 2007, Zimmermann et al. reported that ID was a risk factor for increased thyroid-stimulating hormone (TSH) and decreased free thyroxine (FT4) during pregnancy in women with iodine deficiency in Switzerland (12) . Similarly, Yu et al. reported that ID was an independent risk factor of hypothyroxinemia during early pregnancy in China (13) . Interestingly, Veltri et al. also observed an increased risk of autoimmune thyroiditis (with increased thyroid peroxidase antibody [TPO-ab]) in pregnant women with ID during early pregnancy (14) . As the incidence of ID increases with increasing gestational age, abnormal thyroid function and ID during pregnancy can affect both maternal and infant health. Hence, the aim of this study was to evaluate the relationship between ID and subclinical hypothyroidism, as well as thyroid autoantibodies, during the second trimester of pregnancy.
Subjects and Methods

Study approval and ethics
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All procedures performed in this cross-sectional study were in accordance with the ethical standards of our institutional and/or national research committee and the Helsinki Declaration.
The study protocols were approved by the Medical Ethics Committee of the Fifth People's Hospital of Shanghai, Fudan University (NO. 081). Informed consent was obtained from all participants included in the study.
Study population
According to a previous multicenter survey in China, the median urinary iodine concentration in the Shanghai school-aged population was 170 g/L (15) . From December 2016 to July 2017, 1670 pregnant women were enrolled at the maternity clinic of Shanghai Fifth People's Hospital.
The inclusion criteria for this study were as follows: 1) citizens of China; 2) 13-28 weeks gestational age (calculation based on the last menstrual cycle); and 3) a singleton pregnancy. The following exclusion criteria were applied: 1) multiple pregnancy; 2) history of thyroid disease or other chronic disease (e.g., diabetes, hypertension, tuberculosis); 3) anemia before pregnancy; 4) use of oral contraceptives 3 months before pregnancy or any other drugs potentially affecting thyroid function (e.g., glucocorticoids, dopamine, anti-epileptic drugs); 5) treatment for infertility; 6) positive for HIV or hepatitis B surface antigen (HBsAg); 7) recent blood transfusion; 8) recent infection of the respiratory system, digestive system, urinary system, cardiovascular system, and reproductive system, with or without a fever; 9) history of cancer; 10) history of major mental illness or emotional trauma; or 11) recent physical trauma. We excluded 78 women for the following reasons: not Chinese, 6; twin pregnancy, 7; diagnosed with hyperthyroidism, which was treated with chronic medication before pregnancy, 27; positive for HbsAg, 32; previous infertility treatment, 5 ; and blood transfusion in the past 3 months, 1. Thus, a total of 1,592 pregnant women were enrolled in the study (Fig. 1 ).
In accordance with the 2011 Asia-Pacific consensus regarding the diagnosis of ID anemia during pregnancy, ID was defined as an SF level <20 g/L and ID anemia was defined as an SF level <20 g/L and hemoglobin (Hb) <110 g/L (2,3). The study population was divided into an ID group mass index (BMI) during the second trimester, with >28.0 kg/m 2 defining obesity.
Data collection
The patients' age, gestational weeks, BMI, past obstetric and medical history, and medication history were recorded. Venous blood samples were collected in the morning (07:00-09:00 am) and stored at -80°C until processing. The samples were used to determine the SF concentration, thyroid function tests (including TSH and FT4), thyroid autoantibody levels (including TPO-ab and TG-ab), and complete blood count (including Hb and red blood cell count).
Thyroid function tests and antithyroid antibodies
The FT4 and TSH reference ranges for non-pregnant women at our institution were 12-22 pmol/L and 0.27-4.20 mIU/L, respectively. The cut-off values for abnormal increased antibody levels were 34 IU/mL for TPO-ab and 115 IU/mL for TG-ab. FT4, TSH, TPO-ab, and TG-ab levels were determined using an electrochemiluminescence immunoassay kit (Roche Diagnostics, Cobas 8000 Analyzer e602 module, Germany), following the manufacturer's instructions. According to the manufacturer, the coefficients of variation (CVs) for TSH, FT4, TPO-ab, and TG-ab were 1.73%-2.44%, 1.73%-2.51%, 4.07%-7.13%, and 4.20%-6.60%, respectively, and the coefficients of variation were 2.05%-4.12%, 2.11%-2.57%, 5.04%-8.49%, and 5.33%-7.22%, respectively.
Iron nutrition: indices and biochemical criteria
SF was measured using an electrochemiluminescence immunoassay kit (Roche Diagnostics, Cobas 6000 Analyzer e601 Module, Germany), following the manufacturer's instructions.
According to manufacturer, the intra-assay CV for SF was 1.38%-4.3%, and the inter-batch CV was 5.11%-7.52%. Hb was determined using the XE 2100 D automatic blood cell analyzer (Japan).
Statistical analysis
Data with a normal or approximately normal distribution are described as mean±standard deviation, and data with a non-normal distribution are expressed as median (minimum-maximum).
Continuous variables were compared between groups using the test for normally distributed data and using the Mann-Whitney U test for non-normally distributed data. The effects of independent variables (e.g., ID, age, BMI) on dependent outcome measures (subclinical hypothyroidism and TAI) were explored by fitting logistic regression models. Logistic regression analysis was used to establish the relationship between ID and subclinical hypothyroidism, as well as TAI. SPSS 17.0 statistical software was used for the statistical analyses, and p<0.05 was considered statistically significant.
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Clinical characteristics of the study population
Of the 1592 study participants, 373 were in the ID group, representing an ID rate of 23.4%.
Obesity (BMI >28.0 kg/m 2 ) was present in 6.3% (100/1592) of the study population and 15% (239/1592) of the women were >35 years of age. Age and BMI in the second trimester were not significantly different between the ID and non-ID groups (p>0.05) ( Table 1) . Gestational age was higher in the ID group than in the non-ID group (18.79±3.78 weeks vs 16.36±2.75 weeks; p<0.05). The test center adopted the German Roche electrochemiluminescence immunoassay kit, as the lower limits of detection for TPO-ab and TG-ab were <5 mIU/L and <10 mIU/L, respectively.
The participants were divided into three groups according to TPO-ab/TG-ab levels: below normal range, normal range, and above normal range. There were no significant differences in SF levels between these three groups (p>0.05; Supplemental Figure 1 ).
In accordance with the 2017 ATA criteria (9) , the rate of subclinical hypothyroidism was 9.2% (146/1592) ( Table 2 ). The TAI group rates were 4.8% (77/1592), 3.5% (55/1592), 11.8% (188/1592), and 3.5% (56/1592) for TAI a , TAI b , TAI c , and TAI d , respectively. There were no significant differences between ID and non-ID groups with regard to the rate of subclinical hypothyroidism or any of the four TAI groups (p>0.05).
Association between iron deficiency and subclinical hypothyroidism or thyroid autoimmunity
Logistic regression analysis with subclinical hypothyroidism as the outcome variable (Table 3) showed that older age was associated with a higher risk of subclinical hypothyroidism after adjusting for other variables includinggestational weeks，age，gestational BMI，iron deficiency.
This association was observed in the models for all TAI groups. The existence of TAI was as an independent risk factor for the occurrence of subclinical hypothyroidism, except when only TG-ab was positive (TAI b group). The odds ratios (ORs) and 95% confidence intervals (CIs) for TAI a , TAI c , and TAI d were 3.923 (2.242, 6.865), 3.910 (2.567, 5.957), and 3.565 (1.804, 7.043), respectively (p<0.001 for all groups). However, ID was not a risk factor for subclinical hypothyroidism (p>0.05).
When the TAI groups were used as outcome variables, logistic regression analysis revealed that ID was a risk factor for only the TAI b group (OR 1.974; 95% CI 1.065, 3.657; p<0.05; Table 4 ).
Subclinical hypothyroidism was a risk factor for the occurrence of TAI a , TAI b , TAI c , and TAI d , with
ORs (95% CIs) of 3.938 (2.243, 6.912), 2.231 (1.010, 4.928), 3.958 (2.596, 6.034), and 3.643 (1.833, 7.240), respectively (p<0.05 for all groups). DOI:10.4158/EP-2019-0220 © 2020 AACE.
Discussion
Because pregnant women require more iron than their non-pregnant counterparts, ID is the most common nutritional deficiency during pregnancy (16, 17) . This study focused on the association between ID and thyroid autoantibodies in pregnant women during the second trimester. Based on an SF <20 g/L, we found that the incidence of ID was 23.4% in women living in Shanghai.We previously reported that the incidence of ID at 13-24 weeks gestation was 11.40% among 209 pregnant women with normal TPO-ab and TG-ab levels in the Minhang District of Shanghai (18) . In 2007, Zimmermann et al. (12) reported a 16% incidence of ID during midtrimester pregnancy in iodine-deficient areas on the edge of Zurich, Switzerland, using SF <15g/L as the diagnostic standard for ID. In 2015, Zhongyan et al. (15) reported a 3.0% incidence of ID during early pregnancy in women with sufficient iodine intake who were TPO-ab negative, using SF <12 g/L as the diagnostic standard for ID. Using the same SF criterion, Veltri et al. (14) found a much higher (35%) incidence of ID during early pregnancy. Because of differences in iodine levels, race, ID diagnostic criteria, and stage of pregnancy, it is not surprising that the incidence of ID in our study differed from the previously reported rates. Differences in ID rates might also reflect differences in dietary proportions and structure (19) .
Our results showed that the incidence of subclinical hypothyroidism (TSH >4.0 mIU/L and normal FT4) was 9.17% during the second trimester of pregnancy. Using the same diagnostic criteria, Zimmermann et al. reported a 0.06% incidence of subclinical hypothyroidism in pregnant women in an iodine-deficient region. (12) Using TSH >4.87 mIU/L and FT4 within the normal range as their diagnostic criteria, Shan et al. found a 3.08% incidence of subclinical hypothyroidism during early pregnancy. In the current study of second-trimester patients, we also found that FT4 was lower and TSH was higher in women with ID than in those without ID. There is a statistical comparison between the pregnant week and T4 levels between the ID group and the IDA group (p<0.05), but there was no significant difference between the two groups in gestational age, BMI and TSH during pregnancy (p>0.05) (Supplemental Table 1 ). In their study of women during early pregnancy living in an iodine-sufficient region, Shan et al. found lower FT4 levels in women with ID than in those without ID but no significant difference in TSH levels between ID and non-ID women.
In another study of FT4 and TSH levels in women with or without ID in early pregnancy, Veltri et al.
reported results similar to ours. The inconsistency between our results and those of previous foreign studies may be attributed to differences in iodine intake, rates of positive thyroid autoantibodies during pregnancy, and race (9) . However, our further logistic regression analysis revealed that ID was not a risk factor for subclinical hypothyroidism in the second trimester of pregnancy. This finding is consistent with the results of the 2015 Chinese study by Shan et al., which DOI:10.4158/EP-2019-0220 © 2020 AACE.
showed that mild ID was a risk factor for mild and severe hypothyroxinemia in early pregnancy, but not subclinical hypothyroidism. (15) The lower FT4 levels in ID patients may be related to changes in TPO activity. TPO, which is a key enzyme in the production of thyroid hormone, is an iron-dependent enzyme; thus, ID can lead to decreased FT4 levels through reduced TPO activity. Serum TSH levels are subsequently increased in a negative feedback manner (20) (21) (22) . In an animal model, Shan et al. (23) found that TPO activity, total T3 and T4 levels, and thyroid follicular volume were lower in rats with ID than in those without ID. In addition to reduced T3 and T4 levels, Beard et al. (24) also found reduced TSH levels and decreased TSH production after thyrotropin-releasing hormone (TRH) stimulation in ID rats, when compared with normal rats. Thyroid hormone response to cold stimulation is also slower in ID animals, which may reflect decreased activity of type I deiodinase, the enzyme responsible for converting T4 to T3 (25) . Although decreased TSH levels were found in ID animals, humans with ID typically have increased TSH levels, reflecting positive feedback by TRH and negative feedback by T3 and T4 on pituitary TSH production. Thus, we speculate that the effects of ferritin on TSH may be indirect, representing reduced feedback inhibition because of decreased FT4 levels.
In a study of women seeking fertility treatment in Belgium, Unuane et al. (26) found that the incidence of TG-ab positivity alone was 5% and the rate of TPO-ab positivity alone was 4%. The rate of both TPO-ab and TG-ab being positive was 8%. In that study, there was no difference in antibody positivity rates between ID and non-ID groups, and logistic regression results suggested that age and gestational weeks were risk factors for TPO-ab and TG-ab positivity. The results of a previous epidemiological survey also showed that in women older than 30 years, there was an increased risk of TAI with increasing age (27) . Interestingly, our study is the first to report that ID was a risk factor only for elevated TG-ab levels, not for increased TPO-ab. Previous studies often focused on TPO-ab and did nor measure TG-ab. Hess et al. (28) reported an association between ID and an increased incidence of TAI, after adjusting for age and diet. ID is known to reduce the activities of other heme-containing enzymes, including cytochrome oxidase and myeloperoxidase (MPO), and women with ID may have increased MPO-ab, which can cross-react with TPO-ab and thus lead to thyroid autoantibody positivity (29) . Currently, the exact mechanisms whereby SF deficiency increases TG-ab levels remain unclear. The relationship between TAI and ID involves complex immune mechanisms, in which both genetic and environmental factors likely play an important role. We speculate that decreased FT4 secondary to ferritin deficiency leads to decreased FT4 feedback inhibition of TSH, thereby increasing TSH levels. Because TSH promotes the expression of TG mRNA (30) and TG antigen, this may lead to increased TG-ab production.
This study has some limitations, suggesting areas for further research. Firstly, this study was a crosssectional study of women during the second trimester of pregnancy, preventing us from exploring DOI:10.4158/EP-2019-0220 © 2020 AACE. causal relationships between ID and changes in FT4, TSH, and thyroid autoantibodies. Future longitudinal studies and measurement of TG antigen expression may provide more information about these relationships. Secondly, we did not measure urine iodine levels in the study population.
Although a Chinese multicenter survey convinced the urine iodine in school-aged children was sufficient in shanghai (15) , dietary iodine requirements were higher in pregnancy than for children, optimal iodine status in school-aged children did not necessarily imply that the pregnant women in the same region had optimal iodine intakes. The relationship between SF and thyroid function in pregnant women living in iodine-deficient and iodine-sufficient areas should be further explored, ideally with documentation of urine iodine levels. Thirdly, the role of inflammation on SF in pregnant women should be considered. Although we found no association between SF and serum interleukin (IL)-4, IL-17, or tumor necrosis factor-7 in 268 women for whom these levels were recorded (data not shown), the relationship between inflammation and SF during pregnancy warrants further exploration.
In conclusion, our results indicate that ID during the second trimester of pregnancy is a risk factor for increased TG-ab, but not for subclinical hypothyroidism or increased TPO-ab. We recommend that ferritin deficiency during pregnancy be corrected as soon as possible to minimize thyroid dysfunction, thereby reducing potential adverse outcomes in the women and their offspring.
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